Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.

Biomarkers, Tumor / genetics Breast Neoplasms / enzymology Female Humans Immunohistochemistry Prognosis RNA, Messenger / genetics Ubiquitin-Conjugating Enzymes / genetics
Breast cancer Lymphovascualr invasion Outcome Prognosis Progression UBE2C

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 06 10 2021
accepted: 19 01 2022
pubmed: 7 2 2022
medline: 31 3 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

The Ubiquitin-conjugating enzyme 2C (UBE2C) is essential for the ubiquitin-proteasome system and is involved in cancer cell migration and apoptosis. This study aimed to determine the prognostic value of UBE2C in invasive breast cancer (BC). UBE2C was evaluated using the Molecular Taxonomy of Breast Cancer International Consortium (n = 1980), The Cancer Genome Atlas (n = 854) and Kaplan-Meier Plotter (n = 3951) cohorts. UBE2C protein expression was assessed using immunohistochemistry in the BC cohort (n = 619). The correlation between UBE2C, clinicopathological parameters and patient outcome was assessed. High UBE2C mRNA and protein expressions were correlated with features of poor prognosis, including high tumour grade, large size, the presence of lymphovascular invasion, hormone receptor negativity and HER2 positivity. High UBE2C mRNA expression showed a negative association with E-cadherin, and a positive association with adhesion molecule N-cadherin, matrix metalloproteinases and cyclin-related genes. There was a positive correlation between high UBE2C protein expression and cell cycle-associated biomarkers, p53, Ki67, EGFR and PI3K. High UBE2C protein expression was an independent predictor of poor outcome (p = 0.011, HR = 1.45, 95% CI; 1.10-1.93). This study indicates that UBE2C is an independent prognostic biomarker in BC. These results warrant further functional validation for UBE2C as a potential therapeutic target in BC.

Sections du résumé

BACKGROUND BACKGROUND
The Ubiquitin-conjugating enzyme 2C (UBE2C) is essential for the ubiquitin-proteasome system and is involved in cancer cell migration and apoptosis. This study aimed to determine the prognostic value of UBE2C in invasive breast cancer (BC).
METHODS METHODS
UBE2C was evaluated using the Molecular Taxonomy of Breast Cancer International Consortium (n = 1980), The Cancer Genome Atlas (n = 854) and Kaplan-Meier Plotter (n = 3951) cohorts. UBE2C protein expression was assessed using immunohistochemistry in the BC cohort (n = 619). The correlation between UBE2C, clinicopathological parameters and patient outcome was assessed.
RESULTS RESULTS
High UBE2C mRNA and protein expressions were correlated with features of poor prognosis, including high tumour grade, large size, the presence of lymphovascular invasion, hormone receptor negativity and HER2 positivity. High UBE2C mRNA expression showed a negative association with E-cadherin, and a positive association with adhesion molecule N-cadherin, matrix metalloproteinases and cyclin-related genes. There was a positive correlation between high UBE2C protein expression and cell cycle-associated biomarkers, p53, Ki67, EGFR and PI3K. High UBE2C protein expression was an independent predictor of poor outcome (p = 0.011, HR = 1.45, 95% CI; 1.10-1.93).
CONCLUSION CONCLUSIONS
This study indicates that UBE2C is an independent prognostic biomarker in BC. These results warrant further functional validation for UBE2C as a potential therapeutic target in BC.

Identifiants

DOI: 10.1007/s10549-022-06531-5 PMID: 35124721 PMC: PMC8960565
pubmed: 35124721
doi: 10.1007/s10549-022-06531-5
pii: 10.1007/s10549-022-06531-5
pmc: PMC8960565
doi:

Substances chimiques

Biomarkers, Tumor 0
RNA, Messenger 0
UBE2C protein, human EC 2.3.2.23
Ubiquitin-Conjugating Enzymes EC 2.3.2.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-539

Informations de copyright

© 2022. The Author(s).

Références

Br J Cancer. 2009 Apr 7;100(7):1055-60
pubmed: 19293801
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Trends Cell Biol. 2006 Jan;16(1):55-63
pubmed: 16337124
Prog Cell Cycle Res. 2003;5:335-47
pubmed: 14593728
Biochem Biophys Res Commun. 2020 Mar 5;523(2):389-397
pubmed: 31870550
Theranostics. 2019 Mar 17;9(7):2036-2055
pubmed: 31037155
Cancer. 2012 Aug 1;118(15):3670-80
pubmed: 22180017
World J Gastrointest Oncol. 2016 Feb 15;8(2):198-206
pubmed: 26909134
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
Histopathology. 2005 Jun;46(6):685-93
pubmed: 15910600
Mol Cancer Res. 2020 Feb;18(2):204-215
pubmed: 31662448
Int J Mol Sci. 2019 May 07;20(9):
pubmed: 31067633
Am J Pathol. 2000 Jun;156(6):2135-47
pubmed: 10854234
Breast Cancer Res Treat. 2021 Jan;185(2):293-305
pubmed: 33073304
Breast Cancer Res Treat. 2020 Jan;179(2):349-357
pubmed: 31679074
PLoS One. 2014 Apr 03;9(4):e93934
pubmed: 24699941
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Nature. 1990 Apr 5;344(6266):503-8
pubmed: 2138713
Int J Cancer. 2005 Sep 1;116(3):340-50
pubmed: 15818618
Ann Oncol. 2013 Dec;24(12):3004-11
pubmed: 24158411
Mod Pathol. 2019 Jul;32(7):967-976
pubmed: 30760857
Pathobiology. 2020;87(4):218-231
pubmed: 32645698
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671201
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
PLoS One. 2013 Jun 27;8(6):e68252
pubmed: 23826382
Cancer Cell Int. 2017 Sep 25;17:83
pubmed: 29021715
Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1665-1671
pubmed: 29630110
J Cancer. 2019 May 21;10(10):2176-2184
pubmed: 31258721
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Essays Biochem. 2002;38:51-63
pubmed: 12463161
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Pathobiology. 2015 Sep;82(3-4):113-23
pubmed: 26330352
Int J Cancer. 2007 Mar 15;120(6):1311-7
pubmed: 17187363
Breast Cancer Res Treat. 2017 Jul;164(2):341-348
pubmed: 28478613
Int J Cancer. 2014 Apr 1;134(7):1617-29
pubmed: 24114735
Biomolecules. 2020 Dec 30;11(1):
pubmed: 33396624
Tumour Biol. 2012 Jun;33(3):723-30
pubmed: 22170434
Ann Oncol. 2012 Jun;23(6):1422-7
pubmed: 22056852
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Cancer Res. 2013 Jul 15;73(14):4474-87
pubmed: 23720052

Auteurs

Yousif Kariri (Y)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.
Department of Clinical Laboratory Science, Faculty of Applied Medical Science, Shaqra University, 33, Shaqra, 11961, Saudi Arabia.
ORCID: 0000-0002-2507-2292

Michael S Toss (MS)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.

Mansour Alsaleem (M)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.
Department of Applied Medical Science, Applied Collage in Unazyzah, Qassim University, Qassim, Saudi Arabia.

Khloud A Elsharawy (KA)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.
Department of Zoology, Faculty of Science, Damietta University, Damietta, 34517, Egypt.

Chitra Joseph (C)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.

Nigel P Mongan (NP)

Biodiscovery Institute, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, NG7 2RD, UK.
Department of Pharmacology, Weill Cornell Medicine, New York, NY, 10065, USA.

Andrew R Green (AR)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.

Emad A Rakha (EA)

Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK. emad.rakha@nottingham.ac.uk.
Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK. emad.rakha@nottingham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Disciplines des sciences naturelles › Chimie › Biochimie › Immunohistochimie › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Diagnostic › Pronostic › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...
Recherchemedicale.com › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-conjugating enzymes › Ubiquitin-conjugating enzyme 2C (UBE2C) is a...